Oppenheimer Maintains Outperform on Abbott Laboratories, Lowers Price Target to $115

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

Oppenheimer analyst Suraj Kalia maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $132 to $115.